Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy.
McClanahan F, Hielscher T, Rieger M, Hensel M, Neben K, Hillengass J, Herfarth K, Ho AD, Witzens-Harig M. McClanahan F, et al. Among authors: herfarth k. Eur J Haematol. 2010 Jul;85(1):11-9. doi: 10.1111/j.1600-0609.2010.01445.x. Epub 2010 Mar 16. Eur J Haematol. 2010. PMID: 20331739 Clinical Trial.
[Use of multimodal treatment for early-stage follicular lymphoma].
Witzens-Harig M, Herfarth K. Witzens-Harig M, et al. Among authors: herfarth k. Dtsch Med Wochenschr. 2009 Sep;134(39):1953-5. doi: 10.1055/s-0029-1237539. Epub 2009 Sep 16. Dtsch Med Wochenschr. 2009. PMID: 19760559 German. No abstract available.
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
König L, Dreyling M, Dürig J, Engelhard M, Hohloch K, Viardot A, Witzens-Harig M, Kieser M, Klapper W, Pott C, Herfarth K. König L, et al. Among authors: herfarth k. Trials. 2019 Aug 30;20(1):544. doi: 10.1186/s13063-019-3614-y. Trials. 2019. PMID: 31470902 Free PMC article.
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study.
Herfarth K, Borchmann P, Schnaidt S, Hohloch K, Budach V, Engelhard M, Viardot A, Engenhart-Cabillic R, Keller U, Reinartz G, Eich HT, Witzens-Harig M, Hess CF, Dörken B, Dürig J, Wiegel T, Hiddemann W, Hoster E, Pott C, Dreyling M. Herfarth K, et al. Hemasphere. 2018 Nov 30;2(6):e160. doi: 10.1097/HS9.0000000000000160. eCollection 2018 Dec. Hemasphere. 2018. PMID: 31723798 Free PMC article.
Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, Didinger B, Buechler P, Heeger S, Herfarth KK, Abdollahi A, Buchler MW, Debus J. Krempien R, et al. Among authors: herfarth kk. BMC Cancer. 2005 Oct 11;5:131. doi: 10.1186/1471-2407-5-131. BMC Cancer. 2005. PMID: 16219105 Free PMC article. Clinical Trial.
263 results